Chico's FAS (CHS) - FREE Research Report

Eisenberg Lee who is EVP - Chief Creative Officer at Chico's FAS sold 15,000 shares at $16.51 on Sept. 20, 2013. Following this transaction, the EVP - Chief Creative Officer owned 73,809 shares meaning that the stake was reduced by 16.89% with the 15,000 share transaction.

The shares most recently traded at $17.02, up $0.51, or 2.99% since the insider transaction. Historical insider transactions for Chico's FAS go as follows:

  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 15,300

The average volume for Chico's FAS has been 2.4 million shares per day over the past 30 days. Chico's FAS has a market cap of $2.7 billion and is part of the services sector and retail industry. Shares are down 7.37% year to date as of the close of trading on Friday.

Chico's FAS, Inc., together with its subsidiaries, operates as a specialty retailer of private branded, casual-to-dressy clothing, intimates, complementary accessories, and other non-clothing items in the United States. The stock currently has a dividend yield of 1.29%. The company has a P/E ratio of 16.8. Currently there are 7 analysts that rate Chico's FAS a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHS - FREE

TheStreet Quant Ratings rates Chico's FAS as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Chico's FAS Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement